PortalPublikationenAflibercept for choroidal neovascularizations secondary to p...

Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study

Standard

Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. / Gliem, Martin; Birtel, Johannes; Herrmann, Philipp; Fimmers, Rolf; Berger, Moritz; Coch, Christoph; Wingen, Almut; Holz, Frank G; Charbel Issa, Peter.

in: GRAEF ARCH CLIN EXP, Jahrgang 258, Nr. 2, 02.2020, S. 311-318.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gliem, M, Birtel, J, Herrmann, P, Fimmers, R, Berger, M, Coch, C, Wingen, A, Holz, FG & Charbel Issa, P 2020, 'Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study', GRAEF ARCH CLIN EXP, Jg. 258, Nr. 2, S. 311-318. https://doi.org/10.1007/s00417-019-04551-4

APA

Gliem, M., Birtel, J., Herrmann, P., Fimmers, R., Berger, M., Coch, C., Wingen, A., Holz, F. G., & Charbel Issa, P. (2020). Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. GRAEF ARCH CLIN EXP, 258(2), 311-318. https://doi.org/10.1007/s00417-019-04551-4

Vancouver

Gliem M, Birtel J, Herrmann P, Fimmers R, Berger M, Coch C et al. Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. GRAEF ARCH CLIN EXP. 2020 Feb;258(2):311-318. https://doi.org/10.1007/s00417-019-04551-4

Bibtex

@article{edc8caa5495945b1809071e8ba3335f4,
title = "Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study",
abstract = "PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.",
keywords = "Adult, Choroid/pathology, Choroidal Neovascularization/diagnosis, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Humans, Intravitreal Injections, Male, Middle Aged, Prospective Studies, Pseudoxanthoma Elasticum/complications, Quality of Life, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Recombinant Fusion Proteins/administration & dosage, Tomography, Optical Coherence, Treatment Outcome, Visual Acuity, Young Adult",
author = "Martin Gliem and Johannes Birtel and Philipp Herrmann and Rolf Fimmers and Moritz Berger and Christoph Coch and Almut Wingen and Holz, {Frank G} and {Charbel Issa}, Peter",
year = "2020",
month = feb,
doi = "10.1007/s00417-019-04551-4",
language = "English",
volume = "258",
pages = "311--318",
journal = "GRAEF ARCH CLIN EXP",
issn = "0721-832X",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study

AU - Gliem, Martin

AU - Birtel, Johannes

AU - Herrmann, Philipp

AU - Fimmers, Rolf

AU - Berger, Moritz

AU - Coch, Christoph

AU - Wingen, Almut

AU - Holz, Frank G

AU - Charbel Issa, Peter

PY - 2020/2

Y1 - 2020/2

N2 - PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.

AB - PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.

KW - Adult

KW - Choroid/pathology

KW - Choroidal Neovascularization/diagnosis

KW - Female

KW - Fluorescein Angiography

KW - Follow-Up Studies

KW - Fundus Oculi

KW - Humans

KW - Intravitreal Injections

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Pseudoxanthoma Elasticum/complications

KW - Quality of Life

KW - Receptors, Vascular Endothelial Growth Factor/administration & dosage

KW - Recombinant Fusion Proteins/administration & dosage

KW - Tomography, Optical Coherence

KW - Treatment Outcome

KW - Visual Acuity

KW - Young Adult

U2 - 10.1007/s00417-019-04551-4

DO - 10.1007/s00417-019-04551-4

M3 - SCORING: Journal article

C2 - 31863395

VL - 258

SP - 311

EP - 318

JO - GRAEF ARCH CLIN EXP

JF - GRAEF ARCH CLIN EXP

SN - 0721-832X

IS - 2

ER -